Precision Serotonergic Therapeutics
First-in-class small molecules designed to selectively engage the 5-HT2A receptor and drive functional restoration across ophthalmology and CNS disease.
Our platform combines receptor-level precision with structure-guided design to generate scalable therapies that regenerate tissue, resolve inflammation, and restore neural circuitry.
Meet the Team
-
Alex Speiser
Co-Founder & Chief Executive Officer
-
Charles Nichols, PhD
Co-Founder & Chief Science Officer
-
David Nichols, PhD
Co-Founder & Head of Chemistry
-
Tim Foster, PhD
Co-Founder & Head of Translational Discovery
-
Allan Shepard, PhD
Chief Development & Operations Officer
-
Gerald Billac, PhD
Director of Preclinical Operations
-
Marina Crowe, MBA
Vice President of Corporate Development
Advisors
Development
Chris Crean
CEO of Xyzagen
External Advisor for PK/PD
Kristin Hanley, JD
President, Mederi
Head of Regulatory and Quality
Jim Chastain, PhD
Former PK Sciences Head, Novartis & Alcon External Advisor for DMPK
Chris Verbicky, PhD
President, PharmaLogic Development
Head of CMC
Rose Verhoeven, PhD
Former Toxicology Director, Aerie
Head of Toxicology
Alan Weiner, PhD
Former Sr. Director of Pharmaceuticals, Alcon External Advisor for CMC-DP
Clinical & Commercial
Rayaz Malik, MBChB, PhD, FRCP
Professor of Medicine, Weill Cornell Medicine
External Neuropathy & AI/CCM Clinical Advisor
Gary Sternberg, MD, MBA
Former CMO, Aerie (acq. by Alcon)
Chief Medical Advisor
Founder and former Medical Director of Pepose Vision Institute External Cornea & Ocular Disease Clinical Advisor
Jay Pepose, MD, PhD
Former Commercial / BD Head at Shire (acq. by Takeda)
External Commercial Advisor
Susan Benton, MBA
Former BD Head of Neuroscience/Ophthalmology, Roche
External Commercial Advisor
Thomas Zioncheck, PhD
Co-founder/CEO of Cajal Neuroscience
External CNS Advisor
